Alterity Therapeutics Limited (ATHE) News
Filter ATHE News Items
ATHE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATHE News Highlights
- For ATHE, its 30 day story count is now at 2.
- Over the past 16 days, the trend for ATHE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ATHE are ASX and DEC.
Latest ATHE News From Around the Web
Below are the latest news stories about ALTERITY THERAPEUTICS LTD that investors may wish to consider to help them evaluate ATHE as an investment opportunity.
Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerMELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 yea |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
Alterity (ATHE) Up on Preclinical Parkinson's Treatment DataData from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease. |
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?Although Alterity Therapeutics revealed encouraging data with its PD therapeutic candidate, ATHE stock still faces challenges. |
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressMELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required. The call will be hosted by Alterity’s CEO Dr. David Stam |
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial DataShares in Alterity Therapeutics soared after the biotech firm disclosed promising new clinical trial data for its Parkinson's disease treatment. |
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that promising new data on the effect of ATH434 in a Parkinson’s disease primate m |
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyMELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural History Study at the recent 34th International Symposium on the Autonomic Nervous System (AAS). The poster enti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning! |
Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The MomentKey Insights Alterity Therapeutics' Annual General Meeting to take place on 28th of November CEO David Stamler's total... |